Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport
Autore:
Meisel, C; Roots, I; Cascorbi, I; Brinkmann, U; Brockmoller, J;
Indirizzi:
Univ Greifswald, Inst Pharmacol, Berlin, Germany Univ Greifswald Berlin Germany ifswald, Inst Pharmacol, Berlin, Germany Epidauros Biotechnol AB, Bernried, Germany Epidauros Biotechnol AB Bernried Germany otechnol AB, Bernried, Germany
Titolo Testata:
CLINICAL CHEMISTRY AND LABORATORY MEDICINE
fascicolo: 9, volume: 38, anno: 2000,
pagine: 869 - 876
SICI:
1434-6621(200009)38:9<869:HTMIDT>2.0.ZU;2-6
Fonte:
ISI
Lingua:
ENG
Soggetto:
GLUTATHIONE-S-TRANSFERASE; N-ACETYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE; TURKISH POPULATION; CYTOCHROME-P450 ENZYMES; P-GLYCOPROTEIN; LYMPHOBLASTIC-LEUKEMIA; ALLELE FREQUENCIES; EPOXIDE HYDROLASE; POOR METABOLIZERS;
Keywords:
pharmacogenetics; drug metabolizing enzymes; polymorphisms; drug transporters; P-glycoprotein;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
58
Recensione:
Indirizzi per estratti:
Indirizzo: Meisel, C Humboldt Univ, Klinikum Charite, Inst Klin Pharmakol, Schumannstr 20-21, D-10098 Berlin, Germany Humboldt Univ Schumannstr 20-21 Berlin Germany D-10098 Germany
Citazione:
C. Meisel et al., "How to manage individualized drug therapy: Application of pharmacogenetic knowledge of drug metabolism and transport", CLIN CH L M, 38(9), 2000, pp. 869-876

Abstract

Significant fractions of health budgets must be spent for treatment of drug side effects and for inefficient drug therapy. Hereditary variants in drug metabolizing enzymes, drug transporters, and drug targets are important determinants of drug response and toxicity and may therefore aid in selection and dosage of drugs. Today there is extensive knowledge of genetic polymorphisms of cytochrome P450 (CYP) enzymes 2A6, 2C9, 2C19, and 2D6; of phase-2 enzymes such as thiopurine S-methyltransferase; and more recently of drugtransporters such as the MDR-1 gene-product P-glycoprotein, affecting a significant share of currently used drugs. However, application of pharmacogenetic knowledge to clinical routine is limited in current practice. To promote the application of pharmacogenetic knowledge in clinical routine, research on genotype-based dose adjustments is still necessary - as is the promotion of faster and cheaper genotype analyses. Furthermore, the benefits of CYP genotype-directed drug therapy should be evaluated in properly designedprospective studies. Once such steps have been successfully taken, drug therapy could well become more prevention-directed and patient-tailored than it is possible today, replacing the current "one drug in one dose for one disease" strategy by a more individualized approach.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 18:17:49